GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Response Genetics Inc (OTCPK:RGDXQ) » Definitions » Operating Margin %

Response Genetics (Response Genetics) Operating Margin % : -96.04% (As of Mar. 2015)


View and export this data going back to 2007. Start your Free Trial

What is Response Genetics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Response Genetics's Operating Income for the three months ended in Mar. 2015 was $-3.64 Mil. Response Genetics's Revenue for the three months ended in Mar. 2015 was $3.79 Mil. Therefore, Response Genetics's Operating Margin % for the quarter that ended in Mar. 2015 was -96.04%.

The historical rank and industry rank for Response Genetics's Operating Margin % or its related term are showing as below:


RGDXQ's Operating Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -8.83
* Ranked among companies with meaningful Operating Margin % only.

Response Genetics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Response Genetics's Operating Income for the three months ended in Mar. 2015 was $-3.64 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2015 was $-19.37 Mil.


Response Genetics Operating Margin % Historical Data

The historical data trend for Response Genetics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Response Genetics Operating Margin % Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.09 -40.87 -128.02 -188.34 -118.50

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -72.60 -75.12 379.57 -96.04 -

Competitive Comparison of Response Genetics's Operating Margin %

For the Diagnostics & Research subindustry, Response Genetics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Response Genetics's Operating Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Response Genetics's Operating Margin % falls into.



Response Genetics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Response Genetics's Operating Margin % for the fiscal year that ended in Dec. 2015 is calculated as

Operating Margin %=Operating Income (A: Dec. 2015 ) / Revenue (A: Dec. 2015 )
=-21.377 / 18.04
=-118.50 %

Response Genetics's Operating Margin % for the quarter that ended in Mar. 2015 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2015 ) / Revenue (Q: Mar. 2015 )
=-3.641 / 3.791
=-96.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Response Genetics  (OTCPK:RGDXQ) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Response Genetics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Response Genetics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Response Genetics (Response Genetics) Business Description

Traded in Other Exchanges
N/A
Address
201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Executives
Roberto Mignone 10 percent owner C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Bridger Management Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Swiftcurrent Offshore Ltd 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
David Schreiber director 15 TROTTERS LANE, MONROE CT 06468
Sam Chawla director 1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Kevin Roy Harris officer: Vice President and CFO 345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael Serruya director C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033
Thomas A Bologna director, officer: Chief Executive Officer 4390 US ROUTE ONE, PRINCETON NJ 08540
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Partners Swiftcurrent 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Bridger Capital Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A Metzger director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451

Response Genetics (Response Genetics) Headlines

From GuruFocus

Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares

By GuruFocus Research GuruFocus Editor 12-14-2009